Akari Therapeutics (AKTX) Earnings Date & Reports

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads)... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

AKTX is expected to report earnings to rise 426.32% to -100 cents per share on September 27

Akari Therapeutics AKTX Stock Earnings Reports

Q2'23

Est.

$-1.00

Q4'24

Beat

by $0.81

Q1'23

Est.

$-0.06

Q4'22

Missed

by $0.08

Q3'22

Beat

by $0.02

The last earnings report on April 15 showed earnings per share of -18 cents, beating the estimate of -100 cents. With 13.55K shares outstanding, the current market capitalization sits at 42.96M.

View a ticker or compare two or three

Compare

AKTX